We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$71.3B
1-Year Est. Return
56.8%
This Fund
S&P 500
This Quarter
Est. Return
+24.89%
1 Year Est. Return
+56.8%
3 Year Est. Return
+170.28%
5 Year Est. Return
+249.16%
10 Year Est. Return
+1,007.9%
AUM
$71.3B
AUM Growth
+$6.48B
(+10%)
Cap. Flow
-$2.43B
Cap. Flow
% of AUM
-3.41%
Top 10 Holdings %
Top 10 Hldgs %
29.48%
Holding
1,130
New
174
Increased
291
Reduced
392
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Devon Energy
DVN
|
+$353M |
| 2 |
Marvell Technology
MRVL
|
+$150M |
| 3 |
Spyre Therapeutics
SYRE
|
+$126M |
| 4 |
BridgeBio Pharma
BBIO
|
+$116M |
| 5 |
Dover
DOV
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Revolution Medicines
RVMD
|
+$713M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$355M |
| 3 |
CTRA
Coterra Energy
CTRA
|
+$289M |
| 4 |
Royalty Pharma
RPRX
|
+$259M |
| 5 |
Eli Lilly
LLY
|
+$236M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.29% |
| 2 | Healthcare | 14.03% |
| 3 | Financials | 12.39% |
| 4 | Industrials | 8.94% |
| 5 | Communication Services | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
General Mills
GIS
$19.8B
| $8.13M | 0.01% |
233,596
-107,500
| -32% | -$3.71M |
|
752
Domino's
DPZ
$10.6B
| $8.06M | 0.01% |
27,239
-500
| -2% | -$165K |
|
|
NMG
753
Nouveau Monde Graphite
NMG
$451M
| $7.95M | 0.01% |
+5,300,000
| New | +$10M |
|
754
California Resources
CRC
$5.04B
| $7.93M | 0.01% |
+150,000
| New | +$9.24M |
|
755
Minerva Neurosciences
NERV
$197M
| $7.88M | 0.01% |
1,419,000
| – | – |
|
756
Tenax Therapeutics
TENX
$79.7M
| $7.86M | 0.01% |
540,126
| – | – |
|
757
Symbotic
SYM
$5.54B
| $7.74M | 0.01% |
172,081
+21,641
| +14% | +$1.1M |
|
758
Phillips Edison & Co
PECO
$4.98B
| $7.7M | 0.01% |
185,000
-265,000
| -59% | -$10.6M |
|
759
Oneok
OKE
$60.4B
| $7.52M | 0.01% |
86,500
-327,200
| -79% | -$28.8M |
|
760
Kilroy Realty
KRC
$4.1B
| $7.49M | 0.01% |
+200,000
| New | +$6.8M |
|
|
MAZE
761
Maze Therapeutics
MAZE
$1.37B
| $7.4M | 0.01% |
248,000
-930,000
| -79% | -$24.4M |
|
|
BIOA
762
BioAge Labs
BIOA
$421M
| $7.35M | 0.01% |
300,000
-200,000
| -40% | -$3.61M |
|
763
Nike
NKE
$55.4B
| $7.35M | 0.01% |
179,061
-833,300
| -82% | -$36.7M |
|
764
Fulcrum Therapeutics
FULC
$293M
| $7.32M | 0.01% |
2,000,000
+1,600,000
| +400% | +$9.73M |
|
765
Ball Corp
BALL
$16B
| $7.32M | 0.01% |
+117,297
| New | +$6.9M |
|
766
Wynn Resorts
WYNN
$9.29B
| $7.25M | 0.01% |
74,700
-600
| -0.8% | -$61.9K |
|
767
Herc Holdings
HRI
$4.84B
| $7.22M | 0.01% |
+50,394
| New | +$6.5M |
|
768
PTC
PTC
$14B
| $7.15M | 0.01% |
62,900
+6,700
| +12% | +$905K |
|
769
Korro Bio
KRRO
$190M
| $7.13M | 0.01% |
540,968
+312,568
| +137% | +$3.88M |
|
|
LMRI
770
Lumexa Imaging Holdings
LMRI
$1.08B
| $7.05M | 0.01% |
625,270
+206,742
| +49% | +$1.89M |
|
771
BP
BP
$118B
| $7.02M | 0.01% |
190,000
-200,000
| -51% | -$8.78M |
|
772
Starwood Property Trust
STWD
$5.87B
| $6.96M | 0.01% |
425,000
+385,000
| +963% | +$6.7M |
|
773
Solventum
SOLV
$15.3B
| $6.92M | 0.01% |
89,722
-50,300
| -36% | -$3.67M |
|
774
Trade Desk
TTD
$6.52B
| $6.88M | 0.01% |
380,600
-12,200
| -3% | -$259K |
|
|
FRMI
775
Fermi Inc
FRMI
$3.54B
| $6.87M | 0.01% |
750,000
-1,500,000
| -67% | -$9.48M |
|
Similar funds
Adage Capital Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Adage Capital Partners held 1,130 positions worth $71.3B, up 10% from $64.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners withdrew a net $2.43B in Q2 2026, closing 128 positions and reducing 392 holdings. Its most notable exit was Centessa Pharmaceuticals, an estimated $355M position sold in full.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 27% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Marvell Technology worth $222M.
- Adage Capital Partners's largest Q2 2026 buy was Marvell Technology: 745,800 shares worth $222M.
- Adage Capital Partners added most to Devon Energy in Q2 2026, an estimated $353M increase.
- Adage Capital Partners's biggest Q2 2026 reduction was Revolution Medicines, cutting an estimated $713M.
- Adage Capital Partners fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $355M.
- Adage Capital Partners's ten largest holdings make up 29% of its $71.3B portfolio in Q2 2026.
- Adage Capital Partners opened 174 new positions and closed 128 in Q2 2026.
- Adage Capital Partners's portfolio value rose 10% quarter-over-quarter to $71.3B.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.